Program

Program Tuesday, June 3, 2014

7:15 AM - 8:15 AM
EDUCATIONAL SYMPOSIA
7:15 AM - 8:15 AM
Room: Room 518abc (5th Floor)
EMERGING ACCESS BARRIERS AND EVIDENCE REQUIREMENTS FOR ONCOLOGY THERAPIES: EXPERIENCES ACROSS THREE COUNTRIES

(Sponsored by Xcenda)

8:30 AM - 2:15 PM
RESEARCH POSTER PRESENTATIONS - SESSION III
8:30 AM - 10:30 AM
WELCOME & SECOND PLENARY SESSION
8:30 AM - 8:35 AM
WELCOME
William H. Crown, PhD bio
2013-2014 ISPOR President and Chief Scientific Officer, Optum Labs, Cambridge, MA, USA
8:35 AM - 8:45 AM
INCOMING PRESIDENTIAL ADDRESS
Adrian Towse, MA, MPhil bio
2013-2014 ISPOR President-Elect and Director, Office of Health Economics, London, UK
8:45 AM - 9:00 AM
2014 ISPOR VALUE IN HEALTH PAPER OF THE YEAR AWARD
Presented by: Michael Drummond, PhD, University of York, Heslington, York, UK, and C. Daniel Mullins, PhD, University of Maryland, Baltimore, MD, USA, Value in Health Co-Editors-in-Chief
AWARDEE: James D. Chambers, PhD, MPharm, MSc bio
Assistant Professor of Medicine, the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, Boston, MA, USA
8:45 AM - 9:00 AM
2014 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH
Presented by: Federico Augustovski, MD, MSc, PhD, Chair, ISPOR Award for Excellence in Methodology of Pharmacoeconomics and Director, Economic Evaluations & HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS), and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina
AWARDEE: Richard Norman, MSc, PhD bio
Senior Research Fellow, Centre for Health Economics Research and Evaluation, University of Technology, Broadway, Sydney, Australia
8:45 AM - 9:00 AM
2014 ISPOR AWARD FOR EXCELLENCE IN APPLICATION OF PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH
Announced by: Daniel C. Malone, PhD, RPh, Chair, ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research Committee, Professor, College of Pharmacy, & Associate Professor, College of Public Health, University of Arizona Tucson, AZ, USA
AWARDEE: Marta O. Soares, MSc bio
Research Fellow, The University of York, Centre for Health Economics, Heslington, York, UK
8:45 AM - 9:00 AM
2014 ISPOR BERNIE J. O’BRIEN NEW INVESTIGATOR AWARD
Presented by: Jalpa Doshi, PhD, Chair, ISPOR Bernie J. O’Brien New Investigator Award Committee, Associate Professor of Medicine, Director, Economic Evaluations Unit, Center for Evidence-based Practice, Director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, and Associate Director, ECRI-Penn AHRQ Evidence-based Practice Center, University of Pennsylvania, Philadelphia, PA, USA
AWARDEE: Josh Carlson, MPH, PhD bio
Assistant Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
9:00 AM - 10:30 AM
SECOND PLENARY SESSION: WHAT ARE THE ADVANTAGES AND DISADVANTAGES OF USING OBSERVATIONAL DATA AS THE BASIS OF DECISION MAKING IN HEALTH CARE? HOW COULD THIS AFFECT THE FUTURE OF RANDOMIZED CONTROLLED TRIALS?
This session will focus on the use of observational data (administrative data as well as prospective observational data) studies in health care decision making. The arguments of randomized controlled trials versus 'real world' observational studies (internal/external validity, bias) will be debated.
Moderator: Leslie Levin, FRCP(Lon), FRCPC bio
Chief Scientific Officer, MaRS EXCITE, Vice President, Evidence Development and Standards, Health Quality Ontario, and Professor of Medicine, University of Toronto, Toronto, ON, Canada
Is It Time to Retire the Randomized Controlled Trial?
Speaker: David Sackett, OC, FRSC, MD, MSc, FRCP bio
Professor Emeritus, Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada
Using Observational Data to Estimate Benefits and Harms of Health Care Interventions
Speaker: David Henry, MB ChB, MRCP, FRCP bio
Senior Scientist, ICES Central and Professor, University of Toronto, Toronto, ON, Canada
The Value of Observational Data in Health Care Decisions
Speaker: Allan M. Korn, MD, FACP bio
Chief Medical Officer Emeritus, Blue Cross and Blue Shield Association (BCBSA), Chicago, IL, USA
10:30 AM - 11:00 AM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III
11:00 AM - 12:00 PM
ISSUE PANELS - SESSION II
Economic Outcomes Research Issues
11:00 AM - 12:00 PM
Room: Room 518abc (5th Floor)

IP6: VALUING TARGETED THERAPIES AND THEIR COMPANION TESTS – ARE WE LEAVING SOME OF THE VALUE ON THE BENCH (OR AT THE BEDSIDE)?

Moderator:

Scott Ramsey, MD, PhD, Member, Fred Hutchinson Cancer Research Center and Professor, School of Pharmacy School of Medicine Institute for Public Health Genetics, University of Washington, Seattle, WA, USA

Panelists:

Adele R. Weston, PhD, Executive Vice President & Senior Scientist, Health Economics and Outcomes Research, Optum, Sydney, Australia

Deborah Marshall, PhD, Associate Professor, Community Health Sciences, University of Calgary, Calgary, AB, Canada

Health Policy Development Using Outcomes Research Issues
11:00 AM - 12:00 PM
Room: Room 520cf (5th Floor)

IP7: HOW CAN WE DEFINE AND ACQUIRE SUFFICIENT EVIDENCE TO SUPPORT REIMBURSEMENT DECISIONS FOR MEDICAL DEVICES?

Moderator:

Mark Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

Panelists:

Pascale Brasseur, EconD, Health Economics and Reimbursement Director, Medtronic International Trading Sarl, Tolochenaz, Switzerland

Mirella Marlowe, MA, MBA, Programme Director, Devices and Diagnostics Systems, National Institute for Health and Care Excellence (NICE), London, UK

Stuart Mealing, MSc, Director of Health Economics, ICON Health Economics, Oxford, UK


11:00 AM - 12:00 PM
Room: Room 710a (7th Floor)

IP8: GUIDELINES AND STANDARDS FOR OBSERVATIONAL STUDIES: ARE WE HEADED FOR DISCOURSE OR HARMONY?

Moderator:

Robert W. Dubois, MD, PhD, Chief Scientist, National Pharmaceutical Council, Washington, DC, USA

Panelists:

Rachael Fleurence, PhD, Program Director, Comparative Effectiveness Research (CER) Methods and Infrastructure Program, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA

Sally C. Morton, PhD, Professor & Chair, Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA

Jean Slutsky, PA, MSPH, Director, Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA


11:00 AM - 12:00 PM
Room: Room 710b (7th Floor)

IP9: THE NEXT FRONTIER FOR RISK-SHARING AGREEMENTS IN THE UNITED STATES: DOES THE CHANGING HEALTH CARE LANDSCAPE BRING NEW PROMISE FOR PARTNERSHIPS BETWEEN MANUFACTURERS AND PAYERS?

Moderator:

Josh J. Carlson, MPH, PhD, Assistant Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

Panelists:

Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK

Peter J. Neumann, ScD, Professor & Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

Use of Real World Data Issues
11:00 AM - 12:00 PM
Room: Room 519ab (5th Floor)

IP10: ARE WE GETTING REAL ABOUT REAL-WORLD EVIDENCE REQUIREMENTS?

Moderator:

Kathleen E. Hughes, MBA, Vice President, Health Economics and Outcomes Research, Avalere Health LLC, Washington, DC, USA

Panelists:

John P. Graham, PharmD, Executive Director, Health Services, Health Economics and Outcomes Research, Bristol-Myers Squibb, Plainsboro, NJ, USA

Richard Lieblich, RPh, Vice President, Industry Relations, MedImpact Healthcare Systems, Inc., San Diego, CA, USA

John Watkins, PharmD, MPH, BCPS, Pharmacy Manager, Formulary Development, Premera Blue Cross, Mountlake Terrace, WA, USA

12:00 PM - 2:15 PM
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
12:15 PM - 1:15 PM
EDUCATIONAL SYMPOSIA
12:15 PM - 1:15 PM
Room: Room 710a (7th Floor)
MEASURING UTILITY FOR ECONOMIC MODELS WITHIN CLINICAL TRIALS: CAN WE DO BETTER?

(Sponsored by RTI Health Solutions)

1:15 PM - 2:15 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION III
2:15 PM - 3:15 PM
ISSUE PANELS - SESSION III
Economic Outcomes Research Issues
2:15 PM - 3:15 PM
Room: Room 710b (7th Floor)

IP11: MOVING BUDGET IMPACT ANALYSIS FORWARD: LEVERAGING BIG DATA TO ENABLE USE IN REAL TIME OPERATIONAL DECISION MAKING

Moderator:

Barry Chaiken, MD, MPH, Chief Medical Information Officer, Infor and Adjunct Professor, Health Information Technology, Boston University, New York, NY, USA

Panelists:

Elizabeth L. Meyers, BSN, MS, Industry Strategy Director, Healthcare Analytics, Infor and PhD Student/Guest Lecturer, Institute for Health Informatics, University of Minnesota, Baldwin, WI, USA

Stephanie Earnshaw, PhD, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA

Andrew J. Knighton, MS, CPA, PhD Candidate, Instructor & Teaching Assistant, Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA

Health Policy Development Using Outcomes Research Issues
2:15 PM - 3:15 PM
Room: Room 710a (7th Floor)

IP12: IS THE US MEDICARE PROGRAM’S USE OF COMPARATIVE EFFECTIVENESS RESEARCH CONSISTENT WITH THE AFFORDABLE CARE ACT’S RESTRICTIONS?

Moderator:

Peter J. Neumann, ScD, Professor & Director, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

Panelists:

Penny Mohr, MA, Senior Vice President, Program Development, Center for Medical Technology Policy, Baltimore, MD, USA

Art Small, MD, Head, Oncology Outcomes Research, US Medical Affairs, Genentech, Inc., South San Francisco, CA, USA

James D. Chambers, PhD, MPharm, MSc, Assistant Professor, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA


2:15 PM - 3:15 PM
Room: Room 518abc (5th Floor)

IP13: IS HTA MORE SIMILAR THAN DIFFERENT ACROSS THE ATLANTIC? COMPARISON OF CANADA AND EUROPE

Moderator:

Lou Garrison, PhD, Professor & Associate Director, Pharmaceutical Outcomes Research & Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA bio

Panelists:

Wim Goettsch, PhD, Project Leader, EUnetHTA WP5 on Relative Effectiveness of Pharmaceuticals and Advisor of International Affairs and Academia, Health Care Insurance Board (CVZ), Diemen, The Netherlands

Adrian D. Griffin, MSc, Vice President, HTA & Market Access Policy, Johnson & Johnson, Buckinghamshire, UK

Tammy Clifford, PhD, Vice President, Strategic Initiatives & Chief Scientist, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada


2:15 PM - 3:15 PM
Room: Room 519ab (5th Floor)

IP14: VALUE-BASED PRICING ACROSS INDICATIONS: ARE THE CONCEPTUAL AND IMPLEMENTATIONAL CHALLENGES WORTH IT?

Moderator:

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK

Panelists:

Ansgar Hebborn, PhD, Head, Global Market Access Policy, F. Hoffmann-La Roche AG, Basel, Switzerland

Jeffrey S. Hoch, PhD, Director, Pharmacoeconomics Research Unit & Co-Director, Canadian Centre for Applied Research in Cancer Control (ARCC), Toronto, ON, Canada

Paolo Daniele Siviero, MS, Head of Economic Strategy & Pharmaceutical Policy, Director of Pharmaceutical Policy Unit, Italian Medicines Agency (AIFA), Rome, Italy

Patient-Reported Outcomes & Patient Preference Research Issues
2:15 PM - 3:15 PM
Room: Room 520cf (5th Floor)

IP15: IS PERSONALIZING ADHERENCE THE SOLUTION FOR HELPING ALL PATIENTS TAKE THEIR MEDICINES CORRECTLY?

Moderator:

Dana P. Goldman, PhD, Leonard D. Schaeffer Chair & Director, Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA, USA

Panelists:

Anupam B Jena, MD, PhD, Assistant Professor of Health Care Policy and Medicine, Harvard Medical School, Cambridge, MA, USA

Ross Maclean, MD, Chief Operating Officer, Precision Health Economics, Los Angeles, CA, USA

Seth Seabury, PhD, Associate Professor of Research, Department of Emergency Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA

3:15 PM - 3:45 PM
BREAK & EXHIBITS VIEWING
3:45 PM - 7:45 PM
RESEARCH POSTER PRESENTATIONS - SESSION IV
3:45 PM - 4:45 PM
WORKSHOPS - SESSION II
Clinical Outcomes Research
3:45 PM - 4:45 PM
Room: Room 518abc (5th Floor)
W8: MULTIVARIATE META-ANALYSIS: USE AND APPLICATIONS
Discussion Leaders:

Sonya J Snedecor, PhD, Director, Health Economics, Pharmerit International, Bethesda, MD, USA

Yin Wan, MS, Associate Scientist, Pharmerit International, Bethesda, MD, USA

Joseph C. Cappelleri, PhD, MPH, MS, Senior Director, Biostatistics, Pfizer Inc, Groton, CT, USA

John William Stevens, PhD, Statistician, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Economic Outcomes Research
3:45 PM - 4:45 PM
Room: Room 519ab (5th Floor)
W9: MODELLING ISSUES IN HIV
Discussion Leaders:

Nicolas Despiégel, MSc, Associate Director, Health Economics & Outcomes Research, OptumInsight, Nanterre, France

Milton Weinstein, PhD, Professor, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA

Miranda Murray, PhD, HO Lead, ViiV Healthcare, Brentford, UK

Rodrigo Refoios Camejo, PhD, Director, Value Evidence & Outcomes, GlaxoSmithKline, Brentford, UK

Health Care Policy Development Using Outcomes Research
3:45 PM - 4:45 PM
Room: Room 710b (7th Floor)
W10: IDENTIFYING HIGH-VALUE TREATMENT POPULATIONS IN CLINICAL TRIALS AND REAL-WORLD DATA
Discussion Leaders:

James Signorovitch, PhD, Vice President, Analysis Group, Inc., Boston, MA, USA

James Shaw, PhD, Associate Director, Cardiovascular/Metabolics, Global Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA

Keith A. Betts, PhD, Manager, Analysis Group, Inc., Boston, MA, USA

Eric Q. Wu, PhD, Managing Principal, Analysis Group, Inc., Boston, MA, USA


3:45 PM - 4:45 PM
Room: Room 710a (7th Floor)
W11: HOW CAN WE USE RANDOMIZED TRIAL DATA TO ASSESS HETEROGENEITY OF TREATMENT EFFECTS? LET ME COUNT THE WAYS
Discussion Leaders:

Robert W. Dubois, MD, PhD, Chief Scientist, National Pharmaceutical Council, Washington, DC, USA

C Daniel Mullins, PhD, Professor, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA

David M Kent, MD, MS, Professor of Medicine, Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

Richard Willke, PhD, Group Lead, Outcomes & Evidence, Pfizer Inc., Peapack, NJ, USA

Patient-Reported Outcomes & Patient Preference Research
3:45 PM - 4:45 PM
Room: Room 520ad (5th Floor)
W12: A FRAMEWORK FOR CONDUCTING INITIAL MEDICATION ADHERENCE RESEARCH
Discussion Leaders:

David Hutchins, MBA, Executive Advisor, Caremark, Scottsdale, AZ, USA

Craig S Roberts, PharmD, MBA, Senior Director, Outcomes Research, Pfizer Inc., New York, NY, USA

John E Zeber, PhD, MHA, Investigator & Associate Professor, Center for Applied Health Research, Scott & White Healthcare, Temple, TX, USA

Andrew M. Peterson, PharmD, PhD, Dean, Mayes College of Healthcare Business and Policy, University of the Sciences, Philadelphia, PA, USA

Use of Real World Data
3:45 PM - 4:45 PM
Room: Room 520be (5th Floor)
W13: EVIDENCE SYNTHESIS AND DECISION MAKING WHEN RANDOMISED EVIDENCE DOES NOT SUFFICE
Discussion Leaders:

Doug Coyle, PhD, Professor, Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada

Karen M Lee, MA, Director, Health Economics, Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada

Brian Hutton, PhD, Adjunct Professor, Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada

Kristian Thorlund, PhD, MSc, Director, Redwood Outcomes, Vancouver, BC, Canada


3:45 PM - 4:45 PM
Room: Room 520cf (5th Floor)
W14: SENSITIVITY OF ESTIMATED TREATMENT EFFECTS FROM PROPENSITY SCORE MATCHING ANALYSES
Discussion Leaders:

Bijan J. Borah, PhD, Assistant Professor, Mayo College of Medicine, Department of Health Sciences, Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA

Henry Henk, PhD, Senior Fellow, OptumInsight, Eden Prairie, MN, USA

William H. Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

5:00 PM - 6:00 PM
WORKSHOPS - SESSION III
Clinical Outcomes Research
5:00 PM - 6:00 PM
Room: Room 710b (7th Floor)
W15: ENHANCING META-ANALYSIS BY CONSIDERING THE CORRELATION BETWEEN TWO OUTCOMES
Discussion Leaders:

Julie Roïz, MSc, Director, UK Operations, Creativ-Ceutical, London, UK

Julie Dorey, MSc, Manager, US Operations, Creativ-Ceutical USA, Chicago, IL, USA

Anne-Lise Vataire, PhD, Lead analyst, Creativ-Ceutical, Paris, France

Economic Outcomes Research
5:00 PM - 6:00 PM
Room: Room 519ab (5th Floor)
W16: CHANGING CYCLE LENGTHS IN MARKOV MODELS: DOING IT THE RIGHT WAY
Discussion Leaders:

Jagpreet Chhatwal, PhD, Assistant Professor, Health Services Research, MD Anderson Cancer Center, Houston, TX, USA

Elamin H Elbasha, PhD, Distinguished Scientist, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA

Health Care Policy Development Using Outcomes Research
5:00 PM - 6:00 PM
Room: Room 710a (7th Floor)
W17: UNDERSTANDING AND MODELING BUSINESS DECISIONS IN MARKET ACCESS AND REIMBURSEMENT USING MULTI-CRITERIA DECISION ANALYSIS TECHNIQUES
Discussion Leaders:

Maarten J. IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands

Kevin Marsh, PhD, Director, Modelling and Simulation and Senior Research Scientist, Health Economics, Evidera, London, UK

Ansgar Hebborn, PhD, Head, Global Market Access Policy, F. Hoffmann-La Roche AG, Basel, Switzerland

Tereza Lanitis, MSc, Senior Research Associate, Evidera, London, UK

Patient-Reported Outcomes & Patient Preference Research
5:00 PM - 6:00 PM
Room: Room 518abc (5th Floor)
W18: PATIENT-REPORTED OUTCOMES (PROs) – USE IN ELECTRONIC MEDICAL RECORDS (EMR) AND IMPLICATIONS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER)
Discussion Leaders:

Tara Symonds, PhD, Head of PRO Center of Excellence, Pfizer Ltd., Tadworth, Surrey, UK

Bryce B. Reeve, PhD, Associate Professor, Lineberger Comprehensive Cancer Center & Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Joseph C Cappelleri, PhD, MPH, MS, Senior Director, Biostatistics, Pfizer Inc., Groton, CT, USA

I Katzan, MD, Director, Neurological Institute Center for Outcomes Research & Evaluation, Cleveland Clinic, OH, USA


5:00 PM - 6:00 PM
Room: Room 520ad (5th Floor)
W19: CHOICE DEFINES VALUE: TURNING PREFERENCES OF MULTIPLE STAKEHOLDERS INTO EVIDENCE FOR HEALTH CARE DECISION MAKING
Discussion Leaders:

Axel C. Mühlbacher, PhD, MBA, Professor of Health Economics and Health Care Management, IGM Institute Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany

Benjamin M Craig, PhD, Associate Member, Health Outcomes & Behavior, Moffitt Cancer Center, Tampa, FL, USA

Juan Marcos González, PhD, Senior Research Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA

Use of Real World Data
5:00 PM - 6:00 PM
Room: Room 520be (5th Floor)
W20: EXPLORING AND VALIDATING ALTERNATIVE METHODS OF USING MULTIPLE DATABASES TO ANSWER COMPLEX LONGITUDINAL RESEARCH QUESTIONS: IS LINKING DATABASES THE ONLY ANSWER?
Discussion Leaders:

Rolin L Wade, RPh, MS, Principal, Health Economics and Outcomes Research, Real World Evidence Solutions, IMS Health, Parsippany, NJ, USA

David Macarios, MBA, Vice President, Health Economics and Outcomes Research, LifeCell Corporation, Bridgewater, NJ, USA


5:00 PM - 6:00 PM
Room: Room 520cf (5th Floor)
W21: DOES CONFOUNDING IN COMPARATIVE EFFECTIVENESS ASSESSMENT ALWAYS MATTER FOR PAYERS’ DECISIONS?
Discussion Leaders:

Billy Amzal, X-Eng, MSc, MPA, PhD, Senior Scientific Vice President, LASER Analytica, London, UK

Lamiae Grimaldi, PharmD, MSc, PhD, Senior Scientific Vice President, LASER Research, Paris, France

Yola Moride, PhD, Professor of Pharmacoepidemiology, Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada

Lucien Abenhaim, MD, PhD, Honorary Professor, London School of Hygiene and Tropical Medicine, London, UK

6:00 PM - 7:45 PM
EXHIBITORS' WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV
6:15 PM - 7:15 PM
ISPOR FORUMS - SESSION II

6:15 PM - 7:15 PM
Room: Room 518abc (5th Floor)
PRO AND OBSRO MEASUREMENT IN RARE DISEASE CLINICAL TRIALS — EMERGING GOOD PRACTICES
Moderator:

Margaret Vernon, PhD, Senior Research Scientist, Outcomes Research, Evidera, London, UK

Speakers:

Katy Benjamin, PhD, Director, Patient Reported Outcomes, ICON Commercialisation and Outcomes, Bethesda, MD, USA

Laurie B. Burke, RPh, MPH, Former Associate Director for Study Endpoints and Labeling Office of New Drugs, CDER, U.S. Food & Drug Administration (FDA) and Founder, LORA Group, LLC, Royal Oak, MD, USA

Eleanor Perfetto, PhD, MS, Professor, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA


6:15 PM - 7:15 PM
Room: Room 519ab (5th Floor)
CONJOINT ANALYSIS - STATISTICAL ANALYSES, RESULTS & CONCLUSIONS GOOD RESEARCH PRACTICES
Moderator:

A. Brett Hauber, PhD, Senior Economist and Vice President, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA

Speakers:

Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

Juan Marcos González, PhD, Senior Research Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA


6:15 PM - 7:15 PM
Room: Room 710a (7th Floor)
RARE DISEASE TERMINOLOGY & DEFINITIONS USED IN OUTCOMES RESEARCH
Moderator:

Zeba Khan, PhD, RPh, Vice President, Strategic Market Access & Policy, Celgene, Summit, NJ, USA

Speakers:

Trevor Richter, PhD, MSc, Research Manager, Health Economics, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada

Robert Babela, PhD, MSc, Head of Department of Public Health, HM, St. Elizabeth University, Bratislava, Slovak Republic


6:15 PM - 7:15 PM
Room: Room 710b (7th Floor)
HOW VARIATION IN HTA PROCESSES AND REQUIREMENTS FOR MOLECULAR DIAGNOSTICS CREATES CHALLENGES FOR MANUFACTURER, PAYER, AND CLINICAL STAKEHOLDERS
Moderator:

Susan Garfield, DrPH, Senior Vice President, Market Access, Health, GfK Market Access, Wayland, MA, USA

Speakers:

Michael Longacre, BS, North American Market Access, Global Health Economics and Reimbursement, Beckman Coulter, Inc., Yamhill, OR, USA

Julie Polisena, MSc, Scientific Advisor, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada

Eric Faulkner, Director, Global Market Access, Quintiles, Durham, NC, USA


6:15 PM - 7:15 PM
Room: Room 520cf (5th Floor)
HEALTH CARE IN AFRICA: CAN BIG DATA IMPROVE OUTCOMES?
Moderator:

Anthony Waka Udezi, PhD, Assistant Dean of Pharmacy and Senior Lecturer, Department of Clinical Pharmacy, University of Benin, Benin City, Nigeria

Speakers:

Gihan Hamdy Elsisi, RPh, MSc, Head of Pharmacoeconomic Unit and Part-time Lecturer of Pharmacoeconomics, Central Administration for Pharmaceutical Affairs, Ministry of Health, Faculty of Pharmacy Helwan University, Cairo, Egypt

Ernest Attuquaye Quaye, BPharm, MPH, Principal Pharmacist, Medical Department, Ghana Cocoa Board, Accra, Ghana

Jacques Snyman, MBChB, MPharmMed, MD, President, ISPOR South Africa Chapter and Director, Product Development, Agility Global Health Solutions, Pretoria, South Africa


6:15 PM - 7:15 PM
Room: Room 520ad (5th Floor)
EXPERIENCES IN UPDATING THE COLOMBIAN BENEFITS PLAN: THE ROLE OF THE NATIONAL HTA AGENCY AND THE MINISTRY OF HEALTH
Moderator:

Andrés Felipe Ruíz, MD, Pharmacoepidemiology Assistant, Audifarma S.A, Bogotá, Colombia

Speakers:

Diego Rosselli, MD, MEd, MHP, Associate Professor, Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana Medical School, Bogotá, Colombia

Hector E. Castro, MD, MSc, Director, Health Technology Assessment Institute (IETS), Bogotá, Colombia

Clarice Alegre Petramale, MD, PhD, Director, National Commission for Incorporation of Technologies (CONITEC), Ministry of Health, Brasília-DF, Brazil


6:15 PM - 7:15 PM
Room: Room 520be (5th Floor)
FACING NEW CHALLENGES IN PHARMACOECONOMIC DEVELOPMENT IN RUSSIA AND POLAND
Moderator:

Pavel Vorobiev, MD, PhD, MSc, President, ISPOR Russia Chapter and Professor & Head of the Research Department on Healthcare Standardization Problems, Post-Graduate Education Department, Sechenov Moscow Medical Academy, Moscow, Russia

Speakers:

Karina Jahnz-Rozyk, PhD, MD, Past-President, ISPOR Poland Chapter and Professor & Head of Department of Immunology & Allergology, Military Institute of Medicine, Warsaw, Poland

Petr V. Novikov, MSc, Professor, Department of Clinical Genetics & Head, Research Clinical Institute for Pediatrics, Pirogov State Medical University, Moscow, Russia

Marina V. Zhuravleva, MSc, Professor & Main Clinical Pharmacologist, Department of Health, Moscow City Government, Moscow, Russia

6:45 PM - 7:45 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION IV
8:00 PM - 11:30 PM
ISPOR SOCIAL EVENT - Enjoy an evening of Jazz under the Montreal Sky!
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2016 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.